---
figid: PMC8657692__ijms-22-13071-g009
figtitle: Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular
  Carcinoma Cells
organisms:
- Homo sapiens
- Mus musculus
- Armoracia rusticana
- Hepatitis B virus
pmcid: PMC8657692
filename: ijms-22-13071-g009.jpg
figlink: /pmc/articles/PMC8657692/figure/ijms-22-13071-f009/
number: F9
caption: Proposed model for the underlying mechanism of lenvatinib in overcoming sorafenib
  resistance. Overexpression of EGFR leads to the activation of ERK and Akt signaling
  to induce sorafenib resistance and promote sorafenib-resistant cell proliferation.
  The underlying advantage of lenvatinib is the inhibition of FGFR4 compared with
  sorafenib. Huh-7SR and Hep-3BSR cells have high FGFR4 expression and the FGFR4-ERK
  signaling pathway is the major pathway to overcome increased EGFR-induced ERK activation.
  Compared with Huh-7SR cells, Hep-3BSR cells showed poor autophagic responsiveness
  to lenvatinib, which may contribute to their partial cross-resistance to lenvatinib.
papertitle: Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular
  Carcinoma Cells.
reftext: Tingting Shi, et al. Int J Mol Sci. 2021 Dec;22(23):13071.
year: '2021'
doi: 10.3390/ijms222313071
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: lenvatinib | sorafenib-resistant | hepatocellular carcinoma | FGFR4 | autophagy
  | microRNA
automl_pathway: 0.9123126
figid_alias: PMC8657692__F9
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC8657692__F9
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8657692__ijms-22-13071-g009.html
  '@type': Dataset
  description: Proposed model for the underlying mechanism of lenvatinib in overcoming
    sorafenib resistance. Overexpression of EGFR leads to the activation of ERK and
    Akt signaling to induce sorafenib resistance and promote sorafenib-resistant cell
    proliferation. The underlying advantage of lenvatinib is the inhibition of FGFR4
    compared with sorafenib. Huh-7SR and Hep-3BSR cells have high FGFR4 expression
    and the FGFR4-ERK signaling pathway is the major pathway to overcome increased
    EGFR-induced ERK activation. Compared with Huh-7SR cells, Hep-3BSR cells showed
    poor autophagic responsiveness to lenvatinib, which may contribute to their partial
    cross-resistance to lenvatinib.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Mdk
  - Ephb2
  - Mapk1
  - Fgfr4
  - Akt1
  - Mtor
  - EGFR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - FGFR4
  - AKT1
  - AKT2
  - AKT3
  - MTOR
---
